Bio-Path Holdings Inc. (NASDAQ: BPTH)
$1.94
+0.0200 ( +1.04% ) 82.9K
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
Market Data
Open
$1.94
Previous close
$1.92
Volume
82.9K
Market cap
$4.06M
Day range
$1.89 - $2.01
52 week range
$1.59 - $30.00
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 15 | Jul 11, 2024 |
8-k | 8K-related | 15 | Jun 14, 2024 |
8-k | 8K-related | 13 | Jun 14, 2024 |
8-k | 8K-related | 21 | Jun 05, 2024 |
8-k | 8K-related | 15 | Jun 03, 2024 |
8-k | 8K-related | 17 | May 30, 2024 |
8-k | 8K-related | 15 | May 15, 2024 |
10-q | Quarterly Reports | 53 | May 14, 2024 |
8-k | 8K-related | 15 | Apr 19, 2024 |
8-k | 8K-related | 20 | Apr 19, 2024 |